A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck.

Trial Profile

A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Indometacin (Primary) ; IRX 2 (Primary) ; Omeprazole (Primary) ; Zinc (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Sponsors IRX Therapeutics
  • Most Recent Events

    • 11 Sep 2017 Results published in an IRX Therapeutics media release.
    • 11 Sep 2017 According to an IRX Therapeutics media release, results from the study have been presented at the European Society for Medical Oncology (ESMO) Annual Congress 2017.
    • 02 Aug 2017 According to an IRX Therapeutics media release, data from this trial will be presented at at the European Society for Medical Oncology (ESMO) Annual Congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top